<DOC>
	<DOCNO>NCT01156350</DOCNO>
	<brief_summary>To date , curative option exist patient relapse refractory stage IV neuroblastoma previous autologous stem cell transplantation . Our preliminary result RIC allo-HSCT ( protocol RICE ) indicate feasability low toxicity allograft heavily pre-treated child . Furthermore RIC SCT immunomagnetic CD3/CD19 graft depletion may allow HHCT low toxicity faster engraftment . CD3/CD19 deplete graft contain CD34+ stem cell also graft-facilitating cell , CD34- progenitor , dendritic natural killer cell may allow stable engraftment participate GvT effect . After haploidentical stem cell transplantation anti tumour activity exert donor derive NK cell could stimulate NK cell injection . Those effect may help reduce relapse rate impove outcome patient . The investigator prospectively evaluate engraftment immune reconstitution .</brief_summary>
	<brief_title>Haplo-identical Hematopoietic Stem Cell Transplantation Following Reduced-intensity Conditioning Children With Neuroblastoma</brief_title>
	<detailed_description>This RICE NK protocol multicenter study Haplo- HSCT use RIC fludarabine ( 180 mg/m2 ) , Busulfan IV ( 3,2 4,8 mg/kg/d ) , TBI 2 gray CD3/CD19 graft depletion . A minimum 8 106 CD34+ cells/kg infuse day 0 . No post graft immunosuppression apply graft contain &lt; 2.5 x 104 CD3+ cells/kg . At Day 30 60 post-graft perform donor CD56+ cell injection . The investigator develop strategy European collaboration work haploidentical stem cell transplantation childhood refractory metastatic solid tumor .</detailed_description>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<criteria>High Risk Neuroblastoma HLA haploidentical family donor patient fast progressive neuroblastoma Lansky &lt; 60 %</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Neuroblastoma - Haplo HSCT - Reduced Intensity Conditioning - immunotherapy NK</keyword>
</DOC>